Drug Profile
Opioid analgesic - Sarfez
Alternative Names: Mu-receptor agonist - Sarfez pipeline, November 2017Latest Information Update: 28 Dec 2021
Price :
$50
*
At a glance
- Originator Sarfez Pharmaceuticals
- Class Opioid analgesics
- Mechanism of Action Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Migraine
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Migraine in USA
- 24 Nov 2017 Preclinical trials in Migraine in USA before November 2017 (Sarfez pipeline, November 2017)
- 24 Nov 2017 Sarfez announces intention to submit NDA to US FDA for Migraine in the second quarter of 2020 (Sarfez pipeline, November 2017)